Published in Cancer Sci on October 01, 2006
Application of pharmacogenomics to vaccines. Pharmacogenomics (2009) 1.30
Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother (2013) 0.98
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med (2011) 0.93
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer (2007) 0.92
Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev (2009) 0.90
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. Evid Based Complement Alternat Med (2013) 0.85
Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy. Cancer Sci (2015) 0.81
Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J Gastrointest Oncol (2015) 0.80
Peptide-Based Treatment: A Promising Cancer Therapy. J Immunol Res (2015) 0.80
Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother (2013) 0.79
Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol (2017) 0.77
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. J Immunol Res (2016) 0.75
Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. PLoS One (2017) 0.75
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp Ther Med (2010) 0.75
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination. Hum Vaccin Immunother (2015) 0.75
Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol (2017) 0.75
Multifunctional Alloys Obtained via a Dislocation-Free Plastic Deformation Mechanism. Science (2003) 2.33
Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 2.05
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
Three or more median sternotomies for patients with valve disease: role of computed tomography. Ann Thorac Surg (2003) 1.58
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer (2002) 1.54
Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J (2010) 1.51
Does intensive management of cerebral hemodynamics and atheromatous aorta reduce stroke after coronary artery surgery? Ann Thorac Surg (2008) 1.50
Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci (2011) 1.43
Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis (2002) 1.32
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23
Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation (2004) 1.18
Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol (2008) 1.11
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem (2010) 1.09
Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation. Circ J (2007) 1.08
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07
Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol (2008) 1.06
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol (2012) 1.03
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med (2005) 1.03
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol (2006) 1.02
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother (2009) 1.02
Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology (2003) 1.01
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci (2007) 1.00
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci (2003) 0.98
Prognostic implications of left ventricular wall motion abnormalities associated with subarachnoid hemorrhage. Int Heart J (2008) 0.98
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother (2003) 0.98
Optical assessment of silicon nanowire arrays fabricated by metal-assisted chemical etching. Nanoscale Res Lett (2013) 0.98
Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis. Clin Exp Nephrol (2009) 0.98
Reconstruction of the dynamic velopharyngeal function by combined radial forearm-palmaris longus tenocutaneous free flap, and superiorly based pharyngeal flap in postoncologic total palatal defect. Ann Plast Surg (2015) 0.97
Effect of orally administered shao-yao-gan-cao-tang (Shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study. Am J Chin Med (2003) 0.96
Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer (2010) 0.96
Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci U S A (2005) 0.96
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (2010) 0.96
Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer (2011) 0.95
Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol (2003) 0.94
Tensilin-like stiffening protein from Holothuria leucospilota does not induce the stiffest state of catch connective tissue. J Exp Biol (2006) 0.94
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate (2005) 0.94
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med (2011) 0.93
The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol (2002) 0.93
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother (2003) 0.92
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol (2012) 0.92
Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups. J Gastroenterol (2011) 0.91
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine (2007) 0.91
Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif (2004) 0.90
Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol (2004) 0.90
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother (2005) 0.90
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci (2014) 0.90
Immunopathologic co-localization of MPO, IgG, and C3 in glomeruli in human MPO-ANCA-associated glomerulonephritis. Clin Nephrol (2013) 0.90
Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int (2003) 0.89
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol (2011) 0.89
Simultaneous assessment of wall motion and coronary flow velocity in the left anterior descending coronary artery during dipyridamole stress echocardiography. J Am Soc Echocardiogr (2003) 0.89
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep (2011) 0.89
High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol (2006) 0.88
Dual myeloperoxidase-antineutrophil cytoplasmic antibody- and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis: a report of four cases. Clin Exp Nephrol (2011) 0.88
A biomechanical study on the effect of premature fusion of the frontosphenoidal suture on orbit asymmetry in unilateral coronal synostosis. Cleft Palate Craniofac J (2010) 0.87
Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants. Eur J Immunol (2009) 0.87
Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis (2002) 0.87
Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate (2004) 0.87
Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci (2009) 0.87
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate (2011) 0.87
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep (2013) 0.86
Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. J Vasc Interv Radiol (2002) 0.86
[MPO-positive cells and extracellular MPO in the glomeruli of MPO-ANCA-associated glomerulonephritis]. Nihon Jinzo Gakkai Shi (2009) 0.86
Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol (2014) 0.85
Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. Evid Based Complement Alternat Med (2013) 0.85
Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res (2009) 0.85
Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci (2007) 0.85
Improvement of carrier diffusion length in silicon nanowire arrays using atomic layer deposition. Nanoscale Res Lett (2013) 0.85
[Case report: a case of medial longitudinal fasciculus syndrome and hypertrophic pachymeningitis in an elderly-woman with systemic lupus erythematosus]. Nihon Naika Gakkai Zasshi (2012) 0.85
Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci (2004) 0.85
Thoracoabdominal or descending aortic aneurysm repair after preoperative demonstration of the Adamkiewicz artery by magnetic resonance angiography. Eur J Cardiothorac Surg (2002) 0.85
A novel transporter of SLC22 family specifically transports prostaglandins and co-localizes with 15-hydroxyprostaglandin dehydrogenase in renal proximal tubules. J Biol Chem (2010) 0.85
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. Dev Comp Immunol (2013) 0.84
Direct coating of gold nanoparticles with silica by a seeded polymerization technique. J Colloid Interface Sci (2003) 0.84
Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J Mol Cell Cardiol (2003) 0.84
CD8 T cells are sufficient to mediate allorecognition and allograft rejection. Cell Immunol (2002) 0.84
Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol (2005) 0.84
Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci (2006) 0.83
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacol Immunotoxicol (2014) 0.83
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci (2007) 0.83
Striated muscle twitchin of bivalves has "catchability", the ability to bind thick filaments tightly to thin filaments, representing the catch state. J Mol Biol (2006) 0.83
Prognostic value of left atrial volume index in patents with first acute myocardial infarction. Eur J Echocardiogr (2011) 0.83
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol (2009) 0.83
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci (2012) 0.83
Detection of Micrococcus luteus biofilm formation in microfluidic environments by pH measurement using an ion-sensitive field-effect transistor. Sensors (Basel) (2013) 0.83
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci (2007) 0.83
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer (2013) 0.83